CVS Health, one of America’s largest pharmacy benefit managers, announced it will once again cover Eli Lilly’s weight-loss medication Zepbound (tirzepatide), marking a significant shift in obesity treatment insurance policy in the United States.

Zepbound, a GLP-1/GIP dual receptor agonist, has demonstrated remarkable weight-loss results in clinical trials, with patients averaging over 15% body weight reduction within a year. Some participants achieved weight loss exceeding 20%. The drug was initially approved by the FDA for obesity treatment in 2023.

Previously, several insurance providers, including CVS, had tightened coverage for GLP-1 weight-loss drugs citing cost concerns. An estimated 40% of U.S. adults meet the criteria for obesity diagnosis, yet fewer than 5% of patients have sustained access to pharmacological treatment.

CVS stated the decision to restore coverage was based on updated clinical evidence and cost-benefit analysis. Growing research shows GLP-1 drugs not only aid weight loss but also reduce cardiovascular disease risks and diabetes complications, prompting insurers to reassess their long-term value.

Eli Lilly welcomed the decision, saying it will enable more eligible patients to access necessary treatment. Analysts predict the GLP-1 drug market will maintain high growth in coming years as more insurers follow suit. The global weight-loss drug market currently exceeds $100 billion and is projected to surpass $200 billion by 2030.

However, affordability challenges persist. Even with insurance coverage, patient out-of-pocket costs can remain high, and some plans maintain strict prescription thresholds requiring patients to attempt other weight-loss methods first.